Faculty Interests Database

Faculty Affairs: Faculty Interests Database Wm. Kevin Kelly

Medical Oncology
Professor of Medical Oncology and Urology
Director, Division of Solid Tumor Oncology
Associate Director, Translational Research
No Image Available
Mailing Address Contact Information
834 Chestnut Street, Suite 314
Philadelphia, Pennsylvania 19107
United States
Phone: 215-503-4490
Fax: 215-503-7515
Expertise and Research Interests
Dr. Kelly received his Bachelors degree from Emory University and his Medical degree from the Philadelphia College of Osteopathic Medicine. He completed his internship and medical residency at Albert Einstein Hospital in Philadelphia and completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City where he stayed on as an attending physician for 15 years prior to moving to Yale University where he was an associate professor of medicine and director of Urologic Oncology at Yale Cancer Center. Currently, Dr. Kelly is a Professor of Medical Oncology and Urology and Director of Solid Tumor Oncology Division at Thomas Jefferson University. He also serves as the Associate Director of Translation Research at the Kimmel Cancer Center in Philadelphia, PA.

He has a longstanding clinical expertise in genitourinary malignancies and oncology drug development; bringing novel agents from the bench to the clinic. Dr. Kelly currently conducts a broad range of clinical investigations in novel biologics and chemotherapeutic agents and continues to be actively involved in the Cooperative Groups. He serves as member of Oncology Drug Advisory Committee for the FDA and the National Cancer Institute Prostate Cancer Task Force. Dr. Kelly has been widely published as an author or co-author of more than 100 manuscripts, chapters and abstracts; and he serves on the several editorial boards and is a reviewer for multiple journals.
Prostate Cancer; Bladder Cancer; Testicualr Cancer; Renal Cancer
  • 1 Kelly WK, and Scher HI: Prostate specific antigen decline after anti-androgen withdrawal. J. Urol 149: 607-609, 1993.
  • 2 Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa S. Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 11: 607-615,1993.
  • 3 Scher HI and Kelly WK. Flutamide withdrawal syndrome: It's impact on clinical trials in hormone-refractory prostate cancer. J. Clin Oncol 11: 1566-1572, 1993.
  • 4 Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone refractory prostate cancer: a trial with 10-ethyl-deaza-aminopterin. Urology 44: 237-242, 1994.
  • 5 Scher HI, Zhang Z, Cohen L, Kelly WK Hormonally relapsed prostatic cancer: lessons from the flutamide withdrawal syndrome. Adv. Urol.8: 61-95,1995.
  • 6 Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Detection of circulating tumors cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13: 1195-2000, 1995.
  • 7 Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urol 46: 142-148, 1995.
  • 8 Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, VlamisV, Dnistrian A, Schwartz M. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 13: 2214-2222, 1995.
  • 9 Kelly WK, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen independent prostate cancer. J.Clin. Oncol 13: 2208-2213,1995.
  • 10 Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and anti-hormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 47(Suppl 1A): 61-69, 1996.
  • 11 Steineck G, Kelly WK, Mazumdar M, Vlamis V, Schwartz M, Scher HI. Acid phosphatase: defining a role in androgen-independent prostatic cancer. J Urol 47: 720-726,1996.
  • 12 Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. JNCI 88:1623-1634,1996.
  • 13 McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF. Phase II Randomized Trial of Gallium Nitrate Plus Fluorouracil Verses Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Advanced Transitional-Cell Carcinoma. J. Clin. Oncol. 15: 2449-2455, 1997.
  • 14 McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heinman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF: A Phase II Trial of Docetaxel in Patients with Advanced or Metastatic Transitional Cell Carcinoma.
  • J. Clin. Oncol. 15: 1853-1857, 1997.
  • 15 Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M: Bicalutamide for Advanced Prostate Cancer: The Natural verses Treated History of Disease. J. Clin. Oncol. 15: 2928-2938,1997.
  • 16 Schwartz LH, Latrenta L, Bonnaccio E, Kelly WK, Scher HI, Panicek DM. Small cell Anaplastic prostate cancer: CT and Prostate-Specific Antigen Correlation. Radiology 208: 735-8, 1998.
  • 17 Bajorin DF, McCaffrey JA, Hilton S, Mazumdar M, Kelly WK, Scher HI, Spicer J, Herr H, Higgins G. Treatment of Patients with Transitional-cell Carcinoma of the Urothelial tract with Ifosfamide, Paclitaxel and Cisplatin: A Phase II Trial. JCO 16: 2772-7, 1998.
  • 18 Scher HI, Kelly WK, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB: Post-therapy Serum Prostate-specific Antigen Level and Survival in Patients with Androgen-independent Prostate Cancer. JNCI 91: 244-25, 1999.
  • 21 Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI: Prognostic Significance of Extent of Disease in Bone in Patients with Androgen-independent Prostate Cancer. JCO 17: 948-957,1999.
  • 22 Kelly WK, Osman I, Reuter V, Curley T, Heston WDW, Nanus DM, Scher HI: The Development of Biologic Endpoints in Patients Treated with Differentiation Agents: An Experience of Retinoids in Prostate Cancer. Clinical Cancer Research 6: 838-846, 2000.
  • 23 Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG, Bajorin DF: Phase I Evaluation of Sequential Doxorubicin + Gemcitabine then Ifosfamide + Paclitaxel + Cisplatin for Patients with Unresectable or Metastatic Transitional Cell Carcinoma of the Urothelial Tract. J. Clin. Oncol.18: 840-846, 2000.
  • 24 Zelefsky MJ, Kelly WK, Scher HI, Lee H, Curley T, Metz E, Schwartz L, Fuks Z, Leibel SA: Results of a Phase II study using estramustine phosphate and vinblastine in combination with high dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. JCO 18: 1942-1953,2000.
  • 25 Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G. Ifosphamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88: 1671-1678, 2000.
  • 26 Kelly WK, Slovin SF: Chemotherapy for androgen independent prostate cancer: myth or reality.
  • Current Oncology Reports 2: 394-401, 2000.
  • 27 Small EJ, Frohlich M, Bok R, Shinohora K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM: A prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. . JCO 18: 3595-3603, 2000.
  • 28 Sherman EJ, Pfister DG, Ruchlin H.S., Rubin D.M., Radzyner MH, Kelleher GH, Slovin S, Kelly WK, Scher HI: The COIN Form: a new tool to collect the invisible costs of androgen independent prostate cancer. Cancer 91(4): 841-853, 2001.
  • 29 Kelly WK, Curley T, Slovin S, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P,
  • Smith M, George D, Oh W, Small E, Schwartz L, Larson S, Tong W, Scher HI: Paclitaxel, estramustine phosphate and carboplatin (TEC) in patients with advanced prostate cancer. JCO 19: 44 -53, 2001.
  • 30 Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI: Her2 Profiling and Targeting in Prostate Cancer: A phase II trial of trastuzumab alone and with paclitaxel. Cancer 94 (4): 980-986, 2002.
  • 31 Morris, MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, DiPaola RS, Rafi M, Rosen N, Scher HI: Phase I trial of BCL-2 antisense of oligonucleotide (G3139) administered by continuous infusion in patients with advanced cancer. Cancer Research 8: 679-683, 2002.
  • 32 Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Liebel S, Humm J, Scardino P, Scher H, Hricak H: Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45: 235-44, 2001.
  • 33 Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. JCO 20: 3972-3982, 2002.
  • 34 Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI: Cytotoxic treatment of aggressive prostate tumors with and without neuroendocrine elements. Acta Oncologica 41: 668-674, 2002.
  • 35 Verbel DA, Heller G, Kelly WK, Scher HI: Quantifying the amount of variation in survival explained by prostate-specific antigen. Clinical Cancer Research 8: 2576-2579, 2002.
  • 36 Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI: HER-2 profiling and targeting in prostate carcinoma. Cancer 94(4):980-6, 2002.
  • 37 Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI. Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to definitive phase III trial. Urology 61: 142-144, 2003.
  • 38 Kelly WK, Zhu, AX, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M, Scher HI: Dose escalation study if intravenous (IV) estramustine phosphate (EMP) in combination with paclitaxel and carboplatin in patients with advanced prostate cancer. Clinical Cancer Research 9: 2098-2107, 2003.
  • 39 Kelly WK, Richon VM, OConnor OO, Curley T, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao J, Rifkind R, Marks P, Scher HI : Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA) administered intravenously. Clinical Cancer Research 9:3578-3588, 2003.
  • 40 Smaletz O, Galskt M, Scher HI, DeLaCruz A, Slovin SF, Morris M, Solit DB, Davar U, Schwartz L, Akhurst T, Heller G, Kelly WK: Phase I study of Epothilone B analogue (BMS-247550) and Estramustine Phosphate in patients with progressive metastatic prostate cancer following castration
  • Annals of Oncology 14: 1518-1524, 2003.
  • 41 Solit DB, Morris M, Slovin S, Curley T, Fallon M, Schwartz L, Larson S, Heller G, Kattan M, Hartley-Asp B, Scher HI, Kelly WK: Clinical experience with intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Castrate, Metastatic Prostate Adenocarcinoma: Cancer 98: 1842-1848, 2003.
  • 42 Konety BR, Eatham ES, Donat SM, Reuter VE, Scardino PT, Dalbagni G, Russo P, Schwartz L, Kantoff PW, Scher HI, Kelly WK: Feasibility of radical prostatectomy following neo-adjuvant chemo-hormonal therapy for patients with high risk or locally advanced prostate: results of a phase I/II study. Journal of Urology 171: 709-713, 2004.
  • 43 Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Volgezang NJ, Small EJ for the Cancer and Leukemia Group B: A phase II study of estramustine, docetaxel and carboplatin with G-CSF support in patients with hormone refractory prostate cancer: CALGB 99813. Cancer 98:2592-2598, 2003.
  • 44 Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Favorable five year outcomes with neoadjuvant and conformal radiation therapy in patients with high risk localized prostate cancer. Urology 64: 90-94, 2004.
  • 45 Scher HI, Eisenberger M, DAmico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logethetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group. J.Clin.Oncol. 22:537-556, 2004.
  • 46 Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL. Preliminary Assessment of Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Outcome in Patients with Prostate Cancer at High Risk for Relapse. Clinical Prostate Cancer 3: 174-181, 2004.
  • 47 Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, DeLaCruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI. High dose calcitrol, zoledronate, and dexamethasone for treatment of progressive prostate carcinoma. Cancer 100(9):186-75, 2004.
  • 48 Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA; Society of Urologic Oncology, Shumberg, Illinois. Society of Urologic Oncology position statement: Redefining the management of hormone-refractory prostate carcinoma. Cancer 103 (1):11-21, 2005.
  • 49 Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N, Scher HI: Safety and Biologic Activity of intravenous BCL-2 Anti-sense Oligonucleotide (G3139) and Taxane Chemotherapy in Patients with Advanced Cancer. Appl Immunohistochem Mol Morphol: 13 (1): 6-12, 2005.
  • 50 Galsky MD, Small EJ, Oh WK, Chen I , Smith DC, Colevas AD, Martone L, Curley T, DeLaCruz A, Scher HI, Kelly WK. Multi-institutional Randomized Phase II Trial of the Epothilone B Analogue Ixabepilone (BMS-247550) with or without Estramustine Phosphate in Patients with Progressive Castrate Metastatic Prostate Cancer. J. Clin Oncol. 1;23(7):1439-46, 2005.
  • 51 Dotan ZA, Bianco Jr FJ, Rabbani R, Eastham JA, Fearn P, Scher HI, Kelly WK, Chen HN, Schoder H, Hricak H, Scardino PT, Kattan MW. The pattern of PSA failure dictates the probability of a positive bone scan in patients with a rising PSA after radical prostatectomy. J. Clin Oncol.23(9):1962-8, 2005.
  • 52 Morris MJ, Akurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI. Fluorodeoxyglucose positron emission tomograghy as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11(9): 3210-6, 2005.
  • 53 Kelly WK, OConnor, Krug, Chiao JH, Heaney M, Curley T, MacGregore B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher HI, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17):3923-31, 2005.
  • 54 Ross RW, Manola J, Hennessy K, Galsky M, Scher HI, Small EJ, Kelly WK, Kantoff PW. Prognostic significance of baseline reverse transcriptase polymerase chain reaction for prostate specific antigen (RT-PCR PSA) and RT-PCR PSA responses in men with hormone refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 11(14):5195-8, 2005.
  • 55 Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial endpoints RECISTing a step backwards. Clin Cancer Res. 11(14):5223-32, 2005.
  • 56 Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer, 4(2): 86-90, 2005.
  • 57 Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first line epothilone-B analog ixbepilone (BMS-247550) therapy. Cancer: 106(1):58-62, 2006.
  • 58 Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol. 23(32):8186-91, 2005.
  • 59 Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, Odonoghue JA, Livingston P, Larson S, Scher HI. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res.11(20):7454-61, 2005.
  • 60 Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 7(4):257-61, 2006.
  • 61 OConnor OA, Heaney ML, Schwartz L, Richardson S, William R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 24(1):166-73, 2006.
  • 62 Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176(1):81-6, 2006.
  • 63 Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, Caravelli J, Yeung H, Kris MG, Gomez J, Miller VA, D'Andrea G, Scher HI, Norton L, Hudis C. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res. ;12(20 Pt 1):6100-5, 2006.
  • 64 Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain M, Wilding G, Gross M, Hutcheon D, Small EJ: Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients: a randomized phase II study of ixabepilone or mitoxantrone and prednisone. Cancer 110(3):556-63, 2007.
  • 65 Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G,
  • Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 13(6):1775-82, 2007.
  • 66 Morris MJ, Beekman KW, Kelly WK, Slovin S, Solit D, Shaffer D, Schwartz L, Chu E, Eicher C, Heller G, Delacruz A, Curley T, Scher H. Phase II Trial of Bortezomib Alone and with Prednisone for the Treatment of Castrate Metastatic Prostate Cancer. J Urol. 178(6):2378-83, 2007.
  • 67 Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI.A polyvalent vaccine for high-risk prostate patients: "are more antigens better?" Cancer Immunol Immunother. 56(12):1921-30, 2007.
  • 68 Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 11:994-1000, 2007.
  • 69 Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Heller G, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M: Design and Endpoints of Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2). J Clin Oncol. 26(7):1148-59, 2008.
  • 70 Galsky MD, Eisenberger MA, Moore-Cooper S, Kelly WK, Slovin S, DeLaCruz A, Lee Y, Webb I, Scher HI. Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate, MLN2704, in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 26(13):2147-54, 2008.
  • 71 Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigations. Lab Invest 88 (9):962-72, 2008.
  • 72 Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer. Urology. 72(3):474-80, 2008.
  • 73 Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger Anne, Vogelzang N, Clamon GH, Leonard J, Kelly WK, Small EJ: A Phase II Study of Estramustine, Docetaxel and Exisulind in Patients with Hormone-Refractory Prostate Cancer (HRPC): Results of Cancer and Leukemia Group B (CALGB) 90004. Clinical Genitourinary Cancer. Clin Gentourinary Cancer 6 (2):110-6, 2008.
  • 74 Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, for the Cancer and Leukemia Group B. Multi-center Phase II Study of Neo-Adjuvant Paclitaxel, Estramustine Phosphate, and Carboplatin (TEC) plus Androgen Deprivation Prior to Radiation Therapy in Patients with Unfavorable-Risk Localized Prostate Cancer: Results of CALGB 99811. Cancer 113(11):3137-45,2008.
  • 75 Lee JL, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer. Nature Clinical Practice Oncology. Nat Clin Pract Oncol 6(2):85-92, 2009.
  • 76 Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Solit D, Schwartz L, Stephenson RD, Flatts E, DeLaCruz A, Curley T, Heller G, Jia R, Larson S, Scher HI: Phase I study of Samarium-153 Lexidronam (153Sm-EDTMP) with Docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27(15):2436-42, 2009.
  • 77 Morris MJ, Huang D, Kelly WK, Slovin SF, Solit D, Stephenson RD, Eicher C, DeLaCruz A, Curley T, Schwartz L, Gerald W, Scher HI: Phase I Trial of Exogenous Testosterone in Patients with Progressive Metastatic Prostate Cancer Following Castration. European Urology 56 (2):237-244, 2009.
  • 78 Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B: An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer (CRPC). Clin Cancer Res 15(9):3172-6, 2009.
  • 79 Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI: Anti-epidermal growth factor receptor monoclonal antibody Cetuximab plus doxorubicin in the treatment of castrate resistant prostate cancer. Clinical Genitourinary Cancer 7 (3):77-82, 2009.
  • 80 Regan MM, ODonnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK: Efficacy of Carboplatin-Taxane Combinations in the Management of Castration-Resistant Prostate Cancer: A Pooled Analysis of 7 Prospective Clinical Trials. Ann Oncol 21(2):312-8,2010.
  • 81 Chao HH, Mayer T, Concato J, Rose MG, Uchio E, Kelly WK: Prostate Cancer, Comorbidity and Participation in Randomized Controlled Trial of Therapy. J Investig Med 58 (3): 2010.
  • 82 Picus J, Halabi S, Rini B, Vogelzang N, Whang Y, Kaplan E, Kelly WK, Small E for the Cancer and Leukemia Group B. A phase II study of estramustine, docetaxel and bevacizumab in men with castrate resistant prostate cancer: Results of Cancer and Leukemia Group B (CALGB) 90006. Cancer, 2010 (in press)
  • 83 Kazer MW, Bailey DE, Colberg J, Kelly WK, Carrol P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. Journal of Clinical Nursing, 2010 (in press).
  • 84 Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T, Zhu Y. Genome-wide methylation analysis identifies involvement of TNF-± mediated cancer pathways in prostate cancer. Cancer Letters, 2101 (in press).

Last Updated by Wm. Kelly: Wednesday, March 30, 2011 8:23:30 AM

Back to top